公开(公告)号：CA2408401A1

公开(公告)日：2002-11-06

申请号：CA2408401

申请日：2001-05-03

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  SCHWEIKERT LONI ,  HAHNLEIN WOLFGANG ,  KRAMER KLAUS

IPC: A23L1/30 ,  A23C9/158 ,  A23K1/16 ,  A23L1/305 ,  A23L2/52 ,  A23L33/00 ,  A23L33/15 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/714 ,  A61P9/00 ,  A61P25/00 ,  C07D475/04 ,  A23L1/302 ,  A23L1/29

Abstract: Compositions containing folic acid in combination with 5-methyltetrahydrofol ic acid are disclosed, as well as compositions containing folic acid, 5- methyltetrahydrofolic acid and/or 5-methyltetrahydrofolic acid polyglutamate and a dietary component and/or a dietary preparation and the use thereof.

公开(公告)号：DE10022856A1

公开(公告)日：2001-11-15

申请号：DE10022856

申请日：2000-05-10

Applicant: BASF AG

Inventor： HAEHNLEIN WOLFGANG ,  KRAEMER KLAUS ,  HASSELWANDER OLIVER ,  MUELLER WALTER ,  ECKERT GUENTHER P

IPC: A61K31/385 ,  A61K31/519 ,  C07D339/04 ,  A61K31/7076 ,  A61K45/00 ,  A61P25/00 ,  A61P25/24 ,  A61P25/28 ,  C07D475/04 ,  C07H19/16 ,  A61K31/381

Abstract: The use of lipoic acid (I) (or its derivative or salt) is claimed for the preparation of a medicament for the C1 donor (II)-supported treatment of central nervous system disorders; and the use of (II) is claimed for the preparation of a medicament for the (I)-supported treatment of central nervous system disorders. Independent claims are included for the following: (i) a composition containing (I) (or its salt or derivative), (II), optionally further active agents and a formulation base; and (ii) a commercial package including at least one composition containing (I) (or its salt or derivative) and/or (II), together with instructions for the therapeutic use of (I) in combination with (II).

公开(公告)号：DE102005057178A1

公开(公告)日：2007-07-19

申请号：DE102005057178

申请日：2005-11-30

Applicant: BASF AG

Inventor： KLATT MARTIN JOCHEN ,  HASSELWANDER OLIVER ,  MATUSCHEK MARKUS ,  HAUNERT FRANK

IPC: A61K31/385 ,  A61P3/00

公开(公告)号：DE10253111A1

公开(公告)日：2004-05-27

申请号：DE10253111

申请日：2002-11-13

Applicant: BASF AG

Inventor： AUWETER HELMUT ,  BOHN HERIBERT ,  HASSELWANDER OLIVER ,  RUNGE FRANK

IPC: A23K1/00 ,  A23K1/16 ,  A23L1/30 ,  A61K8/02 ,  A61K8/63 ,  A61K31/575 ,  A61Q1/00 ,  A61Q19/00 ,  C07J9/00 ,  A61K7/00

Abstract: Powdered formulation (A) contains at least one phytosterol (I) and has a mean particle size of 0.01-100 micro-m. An Independent claim is also included for preparation of (A).

公开(公告)号：DE10109073A1

公开(公告)日：2002-09-05

申请号：DE10109073

申请日：2001-02-23

Applicant: BASF AG

Inventor： VOELKEL LUDWIG ,  OFTRING ALFRED ,  HASSELWANDER OLIVER ,  SINDEL ULRIKE ,  KRAEMER KLAUS

IPC: A23L1/30 ,  A23K20/105 ,  A23K20/174 ,  A61K31/375 ,  A61P1/00 ,  A61P1/16 ,  A61P3/02 ,  A61P9/00 ,  C07C215/40 ,  C07D307/62 ,  A23L1/302 ,  A23K1/16

Abstract: Crystalline choline ascorbate (I) is new. An Independent claim is also included for a process for preparing (I).

公开(公告)号：DE10102050A1

公开(公告)日：2002-07-18

申请号：DE10102050

申请日：2001-01-17

Applicant: BASF AG

Inventor： KRAEMER KLAUS ,  HASSELWANDER OLIVER ,  OBERFRANK UWE

IPC: A23K20/158 ,  A23L33/12 ,  A61K31/20 ,  A61K31/202 ,  A61P3/10 ,  A61P9/00 ,  A61P31/18 ,  A61P35/00 ,  A61P37/08 ,  A23L1/29 ,  A23K1/16

Abstract: Food, nutritional supplement, animal feed or medicament preparations (A) containing conjugated cis/trans-octatrienoic acid (I) are new. Independent claims are included for: (1) the production of (A), by adding (I) to the base preparation; (2) a method for supplying calendic acid (Ia), involving adding (Ia) to a carrier fat in feedstuff; and (3) a kit containing (A).

公开(公告)号：AU7050101A

公开(公告)日：2001-11-20

申请号：AU7050101

申请日：2001-05-03

Applicant: BASF AG

Inventor： HAHNLEIN WOLFGANG ,  KRAMER KLAUS ,  HASSELWANDER OLIVER ,  SCHWEIKERT LONI

IPC: A23L1/30 ,  A23C9/158 ,  A23K1/16 ,  A23L1/305 ,  A23L2/52 ,  A23L33/00 ,  A23L33/15 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/714 ,  A61P9/00 ,  A61P25/00 ,  C07D475/04 ,  A23L1/302

Abstract: Compositions are proposed which comprise folic acid in combination with 5-methyltetrahydrofolic acid, and also compositions which comprise folic acid, 5-methyltetrahydrofolic acid and/or 5-methyltetrahydrofolylpolyglutamate and also comprise a dietary component and/or a nutrient preparation, and their use is also proposed.

公开(公告)号：DE10022510A1

公开(公告)日：2001-11-15

申请号：DE10022510

申请日：2000-05-10

Applicant: BASF AG

Inventor： HAEHNLEIN WOLFGANG ,  KRAEMER KLAUS ,  HASSELWANDER OLIVER ,  SCHWEIKERT LONI

IPC: A23L1/30 ,  A23C9/158 ,  A23K1/16 ,  A23L1/305 ,  A23L2/52 ,  A23L33/00 ,  A23L33/15 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/7076 ,  A61K31/714 ,  A61P9/00 ,  A61P25/00 ,  C07D475/04 ,  A61K31/525

Abstract: Composition (I) contains: (a) folic acid; (b) 5-methyl-tetrahydrofolic acid and/or 5-methyltetrahydrofolic acid polyglutamate and (c) a nutrient component and/or a nutrition preparation, provided that if (c) is a nutrient component, then the amount of (b) in the overall composition (I) is greater than that in (c). Alternatively (c) may be absent if (b) is 5-methyl-tetrahydrofolic acid.

公开(公告)号：DE10354380A1

公开(公告)日：2005-06-16

申请号：DE10354380

申请日：2003-11-20

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  JENTZSCH AXEL ,  SCHEIN KARIN ,  HAREMZA SYLKE

IPC: A61K8/34 ,  A61K8/60 ,  A61K8/97 ,  A61Q1/02 ,  A61Q5/00 ,  A61Q17/00 ,  A61Q19/00 ,  A61Q19/08 ,  C07G1/00 ,  A61K7/00

公开(公告)号：AT271866T

公开(公告)日：2004-08-15

申请号：AT01963002

申请日：2001-09-11

Applicant: BASF AG

Inventor： HASSELWANDER OLIVER ,  KRAEMER KLAUS ,  BALDENIUS KAI-UWE ,  KLATT MARTIN JOCHEN ,  SCHWEIKERT LONI

IPC: A61K31/381 ,  A23L1/30 ,  A61K31/00 ,  A61K31/202 ,  A61K31/385 ,  A61P3/10 ,  A61P9/10 ,  A61P13/12 ,  A61P25/02 ,  A61P27/02 ,  A61K31/20

Abstract: The present invention relates to the use of lipoic acid, a physiologically acceptable derivative or salt thereof and one compound of the formula I H3C-(CH2)n1-(CH=CH)n3-(CH2)n2-COOH I in which n1, n2 have, independently of one another, the value of an integer from 3 to 9, n3 has the value of an integer from 2 to 6, and the number of carbon atoms is 18, 20 or 22, a physiologically acceptable derivative or salt thereof, for nutritional supplementation, in functional foods and for therapeutic purposes in the treatment of diabetic disorders. Compositions having a corresponding active ingredient combination, and compositions in the form of commercial packs with corresponding combination products or single-drug products for combined use are also described.